摘要:近期,美国食品与药品监督管理局(FDA)同意加速批准Ocalica(奥贝胆酸),与UDCA(熊去氧胆酸)相结合,用于那些使用UDCA治疗后疗效不佳,或无法耐受UDCA的原发性胆汁性肝硬化成年患者的治疗当中。原发11生胆汁性肝硬化(PBC)是一种慢性疾病,可导致患者胆管出现炎症并受损。胆管受损后,残存在肝脏中的胆汁会慢慢地破坏肝细胞,导致肝硬化并出现瘢痕组织。随着肝硬化的加重,肝脏中的瘢痕组织也随之增加。最终,肝脏将失去其正常功能。如果不接受治疗,
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering